Back to search results

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Abroad (travel likely)RecruitingPHASE2

Conditions

Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope Medical Center, Duarte, California, United States

    Contact: Study coordinator (Thanh Nga Doan) · tdoan@coh.org · 626-256-4673
    Contact: Principal Investigator (Thanh Nga Doan)

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Rachel Freedman, MD) · Rachel_Freedman@dfci.harvard.edu · 617-632-3000
    Contact: Principal Investigator (Rachel Freedman, MD)

  • University of Rochester, Rochester, New York, United States

    Contact: Study coordinator (Allison Magnuson, MD) · allison_magnuson@urmc.rochester.edu · 585-602-5085
    Contact: Study coordinator (MD)
    Contact: Principal Investigator (Allison Magnuson)
Study leads

  • Thanh Nga E Doan, MD

    Principal Investigator

    City of Hope Medical Center

View source on ClinicalTrials.gov(opens in a new tab)